Thermo Fisher Scientific Inc. is investing $150 million in its Pharma Services business to provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing, in Monza and Ferentino, Italy, and Greenville, NC.
The sites will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next two years.

“These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise,” said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. “We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them.”